Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor-T cell (CAR-T) therapy shows promise for hematologic cancers.
• CAR-T therapy has limited effectiveness against solid tumors.

Purpose of the Study:

• To enhance CAR-T cell function and efficacy against solid tumors.
• To develop a novel in vivo vaccine-boosting strategy for CAR-T cells.

Main Methods:

• Designed amphiphile CAR-T ligands (amph-ligands) that target lymph nodes.
• Administered amph-ligands to decorate antigen-presenting cells and prime CAR-T cells in situ.
• Evaluated CAR-T cell expansion, polyfunctionality, and antitumor activity in immunocompetent mouse models.

Main Results:

• Amph-ligand administration led to massive CAR-T cell expansion.
• Enhanced CAR-T cell polyfunctionality and improved antitumor efficacy in preclinical models.
• Demonstrated a generalizable strategy applicable to existing CAR-T designs.

Conclusions:

• In vivo vaccine-boosting with amph-ligands represents a promising strategy to overcome CAR-T therapy limitations in solid tumors.
• This approach offers a simple, non-human leukocyte antigen-restricted method to enhance CAR-T functionality for broad clinical application.